SCHEMBL16201347

SCHEMBL16201347

CCCN(C)Cc1c[nH]nc1-c1ccc(Cl)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 2/20 0.38
ALDH1A1 P00352 1/20 0.34
CARM1 Q86X55 2/20 0.34
PRMT1 Q99873 2/20 0.34
HTT P42858 2/20 0.33
TSPO P30536 2/20 0.33
NR1I2 O75469 1/20 0.33
ABCB11 O95342 1/20 0.33
ALB P02768 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA1 P30542 1/20 0.33
OPRM1 P35372 1/20 0.33
DRD3 P35462 1/20 0.33
OPRK1 P41145 1/20 0.33
PDE4D Q08499 1/20 0.33
KCNH2 Q12809 1/20 0.33
AGER Q15109 1/20 0.33
POLB P06746 2/20 0.33
KDM4E B2RXH2 2/20 0.33
CYP1A2 P05177 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201186 0.88 CARM1 (0.46) ALDH1A1CARM1PRMT1
SCHEMBL16201421 0.87 MEN1 (0.36) CRHR1ALDH1A1CARM1PRMT1KDM4E
SCHEMBL16201416 0.86 STK4 (0.33)
SCHEMBL16201317 0.86 KDM4E (0.34) ALDH1A1KDM4ELMNANPSR1TDP1
SCHEMBL16201341 0.86 MOK (0.37) ALDH1A1CARM1PRMT1ADORA1KMT2A
SCHEMBL16201353 0.85 ALDH1A1 (0.35) ALDH1A1HTTNR1I2KCNH2KDM4E
SCHEMBL16201414 0.85 PRMT1 (0.41) ALDH1A1CARM1PRMT1KDM4ENPC1
SCHEMBL16201375 0.85 NISCH (0.36) CRHR1CARM1PRMT1TSPOADORA1
SCHEMBL16772890 0.84 MAPK11 (0.38) KDM4ESMN1; SMN2CYP3A4CYP2D6TDP1
SCHEMBL16201373 0.84 STK4 (0.44) ALDH1A1CARM1PRMT1ADORA3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CRHR1 3768/4885ALDH1A1 686/4885CARM1 11/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 CRHR1 3785/4885ALDH1A1 895/4885CARM1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.